Tomorrow should be an interesting day, though I'm not expecting anything in particular here. As most I believe know my other major biotech investment is AVXL which has been down substantially as we approach tomorrow. Why? Because tomorrow the European advisory committee will make a recommendation to the regulators to either approve, or not. It's fairly certain the regulators will go along with whatever the committee recommends in roughly 30 to 60 days.
It's a question because like our results, their results aren't perfect. I have little doubt that many with Alzheimer's are benefitting from their drug, much the same way many here are benefitting with DCVax-L. No doubt, in both companies there is some doubt, but if there weren't, both companies would be trading dramatically higher than they are now, and the potential to go dramatically higher on approval wouldn't be nearly as great as approval would be built into their price.
It's unfortunate, but new groundbreaking technology almost always involves taking risk while tweaking an existing product for slight improvement is nearly a sure thing for approval, though it doesn't greatly move the stock price. it keeps the customers coming. It certainly has greater risk to invest in newer dynamic technology, in IMGN it took nearly 4 decades, but it does pay off and I believe that both these companies have the same sort of potential, but I didn't invest in them decades ago when they were totally in their infancy. I'll know tomorrow if AVXL could gain approval shortly, and I really don't think it will be that much longer before we know about NWBO.
Gary
Bullish
Market Data 
Markets 
AI
